Get the Stockscreener App
143.54
2.83%
-4.18
After Hours:
142.09
-1.45
-1.01%
Icon Plc stock is traded at $143.54, with a volume of 568.50K.
It is down -2.83% in the last 24 hours and up +23.34% over the past month.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
See More
Previous Close:
$147.72
Open:
$148.88
24h Volume:
568.50K
Relative Volume:
0.50
Market Cap:
$10.99B
Revenue:
$8.24B
Net Income/Loss:
$222.68M
P/E Ratio:
52.77
EPS:
2.7203
Net Cash Flow:
$888.99M
1W Performance:
-5.45%
1M Performance:
+23.34%
6M Performance:
-21.33%
1Y Performance:
-2.38%
1-Day Range:
$142.93
$148.88
1-Week Range:
$142.93
$154.27
52-Week Range:
$66.57
$211.00
Icon Plc Stock (ICLR) Company Profile
Compare ICLR vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
143.54 | 11.31B | 8.24B | 222.68M | 888.99M | 2.7203 |
TMO
Thermo Fisher Scientific Inc
|
472.63 | 176.04B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
181.35 | 128.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
573.00 | 44.96B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
128.34 | 36.88B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
360.54 | 35.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-23-26 | Upgrade | Jefferies | Hold → Buy |
| Feb-18-26 | Upgrade | TD Cowen | Hold → Buy |
| Feb-17-26 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Feb-12-26 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-12-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-08-26 | Downgrade | Truist | Buy → Hold |
| Dec-15-25 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-13-25 | Initiated | BMO Capital Markets | Market Perform |
| Sep-09-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-03-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Aug-21-25 | Downgrade | Citigroup | Buy → Neutral |
| Jul-24-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-29-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-14-25 | Downgrade | TD Cowen | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Jan-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Neutral |
| Sep-18-24 | Initiated | Leerink Partners | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| Dec-15-23 | Initiated | Truist | Buy |
| Sep-13-23 | Initiated | TD Cowen | Outperform |
| Jan-17-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Jan-13-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-09-22 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-07-22 | Initiated | UBS | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-12-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Sep-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-21 | Initiated | Citigroup | Neutral |
| Apr-13-21 | Resumed | BofA Securities | Neutral |
| Apr-01-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-03-21 | Initiated | Barclays | Equal Weight |
| Mar-01-21 | Upgrade | UBS | Neutral → Buy |
| Feb-26-21 | Upgrade | Truist | Hold → Buy |
| Jul-24-20 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-20-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Sep-23-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jul-26-19 | Upgrade | UBS | Sell → Neutral |
| Jan-25-19 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-09-18 | Initiated | UBS | Sell |
| Apr-03-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-18 | Reiterated | Mizuho | Neutral |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
| Oct-27-17 | Reiterated | Barclays | Equal Weight |
| Sep-11-17 | Initiated | BofA/Merrill | Buy |
| Jul-31-17 | Upgrade | SunTrust | Hold → Buy |
| Jul-27-17 | Reiterated | Mizuho | Neutral |
| Jun-29-17 | Upgrade | Jefferies | Hold → Buy |
View All
Icon Plc Stock (ICLR) Latest News
Greenskeeper Asset Management Increased Its Holdings in ICON Plc (ICLR) Amid Market Fear - Insider Monkey
ICON Plc (ICLR) Stock Analysis: Navigating Growth With Strategic Clinical Innovations - DirectorsTalk Interviews
ICLR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
TD Cowen Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $164 - Moomoo
A Look at Icon PLC (ICLR) After 4.7% Decline -- GF Value $233.73 vs Price $144.59 - GuruFocus
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $105 to $120 - Moomoo
Daily Brief Health Care: Parabilis Medicines, Integral Diagnostics, Healthequity Inc, ICON PLC, KT Medical Service, Leong Guan Holdings, Oramed Pharmaceuticals , Otsuka Holdings, Crism Therapeutics, TransCode Therapeutics and more - Smartkarma
ICON plc options imply 3.1% move in share price post-earnings - TipRanks
Should I Buy ICLR (ICON Public Limited Company) | AI Analysis, Technical & News Insights - Kavout
ICON Stock Valuation vs Peers: Is ICLR Cheap Enough? - Yahoo Finance
Asset turnover of ICON Plc – XETR:IJF - TradingView
Price to book ratio of ICON Plc – XETR:IJF - TradingView
EBIT of ICON Plc – XETR:IJF - TradingView
ICLR Earnings Reset: What the Accounting Probe Changed - TradingView
ICON PLC (ICLR) director Kevin Francis Egan files initial Form 3 - Stock Titan
ICON PLC (ICLR) director Jeffrey Thomas Elliott files Form 3 showing no holdings - Stock Titan
ICON Stock Jumps Again After Accounting Cloud Clears, One Risk Lingers - Bez Kabli
Icon PLC: Q4 Earnings Snapshot - AOL.com
A Look at Icon PLC (ICLR) After 4.6% Gain -- GF Value $232.63 vs Price $143.90 - GuruFocus
ICON plc Experiences Valuation Adjustment Amidst Competitive Market Landscape - Markets Mojo
ICON (ICLR) Is Up 20.8% After 2026 Outlook, Buyback And Governance Shake-UpHas The Bull Case Changed? - Yahoo Finance
William Blair Maintains Icon PLC(ICLR.US) With Buy Rating - Moomoo
Icon PLC (ICLR) Stock Price, Trades & News - GuruFocus
Icon revenue was overstated by $158m between 2023 and 2024 - The Irish Times
TD Cowen raises ICON stock price target on investigation resolution By Investing.com - Investing.com UK
McIntyre Partnerships Sold Its Position in ICON Public Limited Company (ICLR). Here’s Why - Insider Monkey
symbol__ Stock Quote Price and Forecast - CNN
ICON plc Stock 12‑Month Price Target Raised to $151.47, Implies 11% Upside - TradingView
ICON plc stock (IE0005711209): Legal & General stake increase and fresh analyst context - AD HOC NEWS
BofA Securities Maintains Icon PLC(ICLR.US) With Sell Rating, Raises Target Price to $125 - 富途牛牛
BofA raises Icon stock price target to $125 on booking trends - Investing.com UK
ICON Plc (ICLR) Stock Analysis: A Strategic Play In Healthcare With 8.54% Upside Potential - DirectorsTalk Interviews
Icon Plc $ICLR Shares Bought by Legal & General Group Plc - MarketBeat
Why ICON (ICLR) Is Up 16.5% After 2025 Earnings, Accounting Issues And New 2026 Outlook – And What's Next - Sahm
TD Cowen Maintains Icon PLC(ICLR.US) With Buy Rating, Raises Target Price to $164 - 富途牛牛
MSN Money - MSN
Icon PLC Stock Historical Valuations | BSP:ICLR34 - GuruFocus
Icon PLC (BSP:ICLR34) Stock News, Headlines & Updates - GuruFocus
Icon PLC (BSP:ICLR34) Stock Earnings Transcripts - GuruFocus
Icon PLC (BSP:ICLR34) Stock Price & 30 Year Financial Data - GuruFocus
Icon PLC (BSP:ICLR34) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Icon PLC Stock Operating Data - GuruFocus
Icon PLC (BSP:ICLR34) Stock Price, Trades & News - GuruFocus
Icon Plc Q4 Earnings Call Highlights: Key Takeaways from Recent DiscussionNegative Surprise Momentum - thelegaladvocate.com
RBC Capital raises Icon stock price target to $126 on de-risking - Investing.com UK
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $105 to $168 - 富途牛牛
Research Alert: CFRA Maintains Hold Rating On Shares Of Icon Public Limited Company - Moomoo
ICON plc: FY 2025 Shows Reset Before Reacceleration - Seeking Alpha
RBC Capital raises Icon stock price target to $126 on de-risking By Investing.com - Investing.com South Africa
Leerink Partners Downgrades Icon PLC(ICLR.US) to Hold Rating, Raises Target Price to $145 - 富途牛牛
Jefferies Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $135 - 富途牛牛
Icon Plc Stock (ICLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.56%
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):